



**Award most cited
article EJCI 2016**

Award most cited article EJCI 2016

Review

Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention

Dimitrios C. Mastellos, Despina Yancopoulou, Petros Kokkinos, Markus Huber-Lang, George Hajishengallis, Ali R. Biglarnia, Florea Lupu, Bo Nilsson, Antonio M. Risitano, Daniel Ricklin, [John D. Lambris](#)

First published: 9 March 2015

DOI: 10.1111/eci.12419 [View](#)

Cited by (CrossRef): 35 articles



Funding Information

Abstract

There is a growing awareness of the role of the complement system in disease, transcending its traditional role in opsonic cell killing. As the complement system becomes better understood, it has become longer, it has become clearer that the immune system opens new windows of therapeutic opportunity. Indeed, the introduction of the first complement-based inhibitors...

Corresponding author

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

✉ Correspondence to: John D. Lambris, Department of Pathology and Laboratory Medicine, University of Pennsylvania, 401 Stellar-Chance labs 422 Curie Boulevard, Philadelphia, PA 19104-6100, USA. Tel.: +1 215 746 5765; fax: +1 215 573 8738;

e-mail: lambris@upenn.edu

[Search for more papers by this author](#)



[View issue TOC](#)
Volume 45, Issue 4
April 2015
Pages 423–440

role in human physiology and the complement system for pathogen clearance and complement activation grows. The immune system opens new windows of therapeutic opportunity. Indeed, the introduction of the first complement-based inhibitors...



Award most cited article EJCI 2016

- 2016 Most cited article published in EJCI, with **45** citations:

Title: "Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction", by

Authors: G. Boden and G. I. Shulman

DOI: 10.1046/j.1365-2362.32.s3.3.x, Vol. 32;

Volume 32, Issue s3, Pages: 14–23, Published June 2002

- Most cited article in the 2016 impact factor period (published 2014-2015) with **21** citations:

Title: "Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention"

Authors: Dimitrios C. Mastellos et al.

DOI: 10.1111/eci.12419;

Volume 45, Issue 4, Pages: 423-440, Published April 2015.

